The cost for pathogen testing kits are going up. The pricing is the key. Lets say one clinic was to acquire a kit from the states and get it shipped and wait for it to arrive. The true cost on the balance sheet is cost+delivery and real impact for the clinic is cost+ delivery + time + expected revenue loss.
I don't buy the argument that gross margins are here to stay where they are. It can easily explode and future PE will expand. There's so much opportunity here.
So far there's only been two Australian companies approved for legal sale of Covid 19 test kits in Australia. One is private. Others are Chinese.
Massive opportunities out there.
I guess thick stock will keep going up in increments as they keep signing clients, just like any other medical device supplier.
- Forums
- ASX - By Stock
- GSS
- Ann: Appendix 4C & quarterly update
Ann: Appendix 4C & quarterly update, page-24
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GSS (ASX) to my watchlist
(20min delay)
|
|||||
Last
70.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $158.8M |
Open | High | Low | Value | Volume |
70.0¢ | 70.0¢ | 68.5¢ | $4.706K | 6.83K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 10880 | 68.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
70.0¢ | 24999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 10880 | 0.680 |
1 | 1528 | 0.655 |
1 | 100000 | 0.650 |
1 | 1000 | 0.550 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.700 | 24999 | 1 |
0.710 | 20000 | 1 |
0.730 | 14325 | 1 |
0.740 | 1400 | 1 |
0.750 | 19024 | 2 |
Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
Featured News
GSS (ASX) Chart |